Lucknow Speciality Pharma
Daratumumab Injection
- Innovator Brand Name – Darzalex
- API – Daratumumab
- Packaging – Single-Dose Vial
- Strength – 100 mg/5 ml & 400 mg/20 ml
- Manufacturer Name – Johnson & Johnson
What is daratumumab used for?
Daratumumab Injection is an anti-cancer medication indicated for the treatment of:
Multiple Myeloma: In the patient who had received at least three prior therapies.
Newly Diagnosed Multiple Myeloma: Patients who are not able for autologous stem cell transplant may receive Daratumumab with a combination of the melphalan, bortezomib, and prednisone.
As a Monotherapy: Darazalex can be also taken by the patients with relapsed and refractory multiple myeloma.
Facts of Medicines
DARATUMUMAB DOSAGE
You should receive Daratumumab Injection as an infusion into your vein (Intravenously) by your healthcare provider.
DARATUMUMAB SIDE EFFECTS
- Some most common adverse reactions include fever, tiredness, nausea, diarrhea, shortness of breath, feeling week, decreased appetite, cold-like symptoms, chills, and dizziness.
- Also, severe side effects of Darzalex (Daratumumab) include infusion reactions, vomiting, lung infection, decreased blood cell count and swollen hands, ankles, and feet.
SUPPLIED/STORAGE AND HANDLING
Care should be exercised in the handling of Darzalex (Daratumumab Injection). Darzalex should be retained in their genuine & original packaging in order to protect them from the light. Store permitted between 2-8°C (36-46°F).
- In the case of Neutropenia should be monitored complete blood count periodically during the treatment.
- Patients with previously Hepatitis B infection should talk with your healthcare provider. It can active the Hepatitis B infection again.
- Darzalex contraindicated for the patient with a history of severe hypersensitivity.
- Patients with thrombocytopenia should be monitored closely as well as monitor complete blood cells count while on Daratumumab.
- Patients with Infusion reactions should interrupt the infusion of Daratumumab (Darzalex).
FAQs – Medicine Questions
What are the inactive ingredients of Darzalex(Daratumumab)?
Mannitol, Sodium Acetate Tri-hydrate, Glacial Acetic Acid, Sodium Chloride, Polysorbate 20 and Water for Injection are some Inactive Ingredients.
Is Daratumumab immunotherapy or chemo?
Daratumumab is an immunoglobulin G1 kappa (IgG1κ) human monoclonal antibody. Therefore it is not a chemotherapy medicine. It is a targeted therapy also known as immunotherapy.
Is Daratumumab FDA approved?
Yes. The FDA must first approve generic drugs before they are marketed. The FDA requires that generic drugs must be as high in quality, and as strong, pure and stable as brand name drugs.
Where can I buy Daratumumab Injection?
You can buy Daratumumab Injection from any authorized whole-seller after getting a prescription from a qualified doctor. It is always better to check the credential of the whole-seller/supplier/exporter before buying the product.
The buyer should check the existing law in their home country before importing the product.
What is the procedure to buy Daratumumab Injection?
Patients can simply fill the order form or can send mail at info@lucknowpharma.com Patients can also send WhatsApp messages to +91-9555306364 We will reply ASAP with the details of the Daratumumab Injection price as well as procurement procedure.
Note:- The order will be confirmed only after the receipt of the Valid prescription of the Clinician.
How is Daratumumab given?
Daratumumab is either given in combination with other drugs or alone to treat multiple myeloma. Healthcare professionals give this medicine through intravenous infusion according to the prescribed dosage to the patients.
NEWS / UPDATES
- Janssen-Cilag International NV, Electronic medicines compendium (emc), [ Revised on Dec 2020] [ Accessed on 6th May 2021], https://www.medicines.org.uk/emc/files/pil.7250.pdf
- Janssen Biotech, Inc, US Food and Drug Administration, [ Revised on May 2018] [ Accessed on 6th May 2021], https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761036s013lbl.pdf
- Danai Dima et al; Evaluating Daratumumab in the Treatment of Multiple Myeloma: Safety, Efficacy and Place in Therapy; Cancer Management and Research; Published on 26/08/2020; Accessed on 12/11/2021; https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457558/